A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS

Authors RVL Pharmaceuticals, Inc. -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
Links ClinicalTrials.gov
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America. Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.
Epistemonikos ID: 65f087c17e493ad38892bb38d7593cfd5b2a8d82
First added on: Mar 31, 2022